🇺🇸 FDA
Patent

US 10894061

Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells

granted A61KA61K2035/122A61K2035/124

Quick answer

US patent 10894061 (Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells) held by Regents of the University of Minnesota expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regents of the University of Minnesota
Grant date
Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2035/122, A61K2035/124, A61K2039/515, A61K2039/545